Clinical Trial Update: Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)

View source ↗

Summary

A regulatory post-marketing surveillance study of bortezomib (Velcade) in Korea has completed. The study focused on patients with multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Janssen Korea, Ltd., Korea | Conditions: Multiple Myeloma | Status: COMPLETED